首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Immunosuppressive Therapy Does Not Prevent the Occurrence of Immunoglobulin E–Mediated Allergies in Children and Adolescents With Organ Transplants
【24h】

Immunosuppressive Therapy Does Not Prevent the Occurrence of Immunoglobulin E–Mediated Allergies in Children and Adolescents With Organ Transplants

机译:免疫抑制疗法不能预防免疫球蛋白E介导的儿童和青少年器官移植过敏的发生。

获取原文
           

摘要

BACKGROUND. Allogeneic organ transplantation has become a common procedure in acute and chronic organ failure. The major limitation, rejection of the allograft by the host's immune system, can be limited by various immunosuppressive drugs that target the adaptive T-cell response. Most of these drugs are used in the treatment of allergic diseases as well, suggesting that transplant recipients under long-term immunosuppressive therapy should not develop any sensitizations or at least not show any clinical signs of allergy. Surprisingly, organ-transplanted children and adults do report symptoms of type 1 allergies, such as allergic rhinoconjunctivitis, bronchial asthma, and food allergies. Thus far, mainly case reports and series on the occurrence of allergy after orthotopic liver transplantation exist.OBJECTIVE. Our purpose with this study was to evaluate in a cross-sectional design the prevalence of immunoglobulin E-mediated sensitizations and type 1 allergies in solid organ–transplanted children and adolescents and to identify risk factors.METHODS. Seventy-eight organ-transplanted subjects (50 kidney, 9 lung, 19 liver; mean age: 14.06 ± 5.94 years; range 1.42 to 24.25 years) were studied by standardized interviews (modified International Study of Asthma and Allergies in Childhood [ISAAC] criteria), skin-prick tests, and measurement of specific and total serum immunoglobulin E.RESULTS. Nineteen patients (24.4%) were found to be sensitized to ≥1 common inhalant or food allergens, as reflected by elevated specific immunoglobulin E levels and/or positive skin-prick test results, and 8 subjects (10.3%) additionally reported a corresponding present history of atopic diseases. No severe anaphylactic reactions were reported. No statistically significant associations with gender, kind of transplanted organ, distinct immunosuppressive therapies, and age at time of transplantation or age at investigation were found (χ2 test, Fisher's exact test, and Wilcoxon rank-sum test, respectively). Multiple logistic-regression analysis did not identify any independent risk factor either.CONCLUSION. This study demonstrates that therapeutic immunosuppression does not control sensitizations and clinical manifestation of type 1 allergies in organ-transplanted children and adolescents.
机译:背景。同种异体器官移植已成为急性和慢性器官衰竭的常见方法。主要的局限性,即同种异体移植物被宿主免疫系统排斥的局限性,可能受到靶向适应性T细胞反应的各种免疫抑制药物的限制。这些药物中的大多数也用于过敏性疾病的治疗,这表明接受长期免疫抑制治疗的移植受者不应出现任何致敏作用,或至少不表现出任何过敏的临床体征。出人意料的是,器官移植的儿童和成人确实报告了1型过敏的症状,例如过敏性鼻结膜炎,支气管哮喘和食物过敏。迄今为止,主要存在原位肝移植术后发生变态反应的病例报道和系列报道。我们这项研究的目的是通过横断面设计评估固体器官移植儿童和青少年中免疫球蛋白E介导的致敏性和1型过敏的患病率,并确定危险因素。通过标准化访谈(修正的《国际哮喘与小儿过敏症研究》 [ISAAC]标准)研究了78例器官移植受试者(50个肾脏,9个肺,19个肝脏;平均年龄:14.06±5.94岁;范围1.42至24.25岁)。 ),皮肤点刺试验以及特异性和总血清免疫球蛋白E的测定。发现19名患者(24.4%)对≥1种常见的吸入性或食物过敏原敏感,这通过特异性免疫球蛋白E水平升高和/或阳性皮肤刺刺试验结果得以反映,另外8名受试者(10.3%)报告了相应的存在特应性疾病的历史。没有严重的过敏反应报道。没有发现与性别,移植器官的种类,独特的免疫抑制疗法以及移植时的年龄或研究时的年龄有统计学意义的关联(分别为χ2检验,Fisher精确检验和Wilcoxon秩和检验)。多元logistic回归分析也未发现任何独立的危险因素。这项研究表明,在器官移植的儿童和青少年中,治疗性免疫抑制不能控制1型过敏的致敏性和临床表现。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号